Introduction
The prevalence of allergic diseases in pediatric populations has been extensively studied in recent years.
The comparison of phases I and III of the International Study of Asthma and Allergies in Childhood (ISAAC), conducted at intervals of at least 5 years between phases, revealed an increase in the prevalence of asthma among school-age children and adolescents in most centers included in the study. 1 Although Brazil has a high prevalence of asthma and associated symptoms, in ISAAC phase III most centers had a reduction of those indices among both children and adolescents, and the highest asthma prevalence rates were found in the centers closest to the equator. 2, 3 In Curitiba no differences were found in the prevalence of asthma and probable asthma between phases I and III, which were conducted in 1995 and 2001. 4 Despite extensive knowledge acquired about the epidemiology of asthma among school-age children and adolescents, there is scarce information for the pre-school age groups, particularly infants, for whom asthma diagnoses are more complex and may be confused with other diseases. Wheezing is common in asthma, as well as recurrent wheezing (3 or more wheezing episodes). The Estudio Internacional de Sibilancias en Lactantes (EISL) was created to determine its epidemiology, treatment and risk factors. 5 A study with 30,093 infants aged 12 to 15 months in 17 centers in Latin America, Spain and the Netherlands found that the prevalence of at least one episode of wheezing was 45.2%, and of recurrent wheezing, 20.3%, with greater prevalence rates and severity in Latin American countries than in Europe. Therefore, some factors may be determinant for the development of wheezing in the different regions already evaluated. 6 Different factors associated with recurrent wheezing have been identified, 7 A sample of at least 1,000 infants is enough to detect a 5% prevalence of recurrent wheezing between two centers when one has a prevalence of about 20% at a 95% confidence interval and 80% power. 10 A chi-square test was used for categorical variables, described as proportions, and the Student t test, for continuous variables, presented as means ± standard deviation. The level of significance was set at α < 0.05.
Results
The questionnaire was completed by 3,003 parents of infants (50.7% male infants) in phase I; 45.4% of the infants had at least one wheezing episode, and 22.6% had recurrent wheezing (≥ 3 episodes) with the first episode at 5.5 ± 3.1 months. After 5 years, 1,003 parents completed the same questionnaire in phase III, and 40.6% of the infants (51.1% male infants) had at least one wheezing episode (p = 0.46), 19.8% had recurrent wheezing (p = 0.1) with the first episode at 6.1 ± 3 months (p = 0.06). Changes in severity and physician-diagnosed asthma comparing EISL phases I and III are shown in Table 1 .
Discussion
The repeated use of the same questionnaire to determine period changes in the point prevalence of asthma all over the world has yielded widely varying results. Most regions have seen an increase in prevalence, whereas others had stable rates or even reductions. [1] [2] [3] However, no similar trend has been reported for recurrent wheezing in infants, and one of the few studies that used the same method to determine the epidemiology of wheezing in this population published its results only recently. 6 In our population, wheezing prevalence in EISL phase I was high and infants often had severe symptoms in their first year of life. 11 Of the other six Brazilian cities where the EISL phase I was used, Porto Alegre and Belo Horizonte had the greatest prevalence of recurrent wheezing and symptom severity. 6 Factors that are inherent to each population or environment promote differences in the factors associated with recurrent wheezing documented in Curitiba, Porto Alegre and São Paulo. 7, 12, 13 If there are differences in the epidemiology of infant wheezing between centers, what is the likelihood of finding changes in results some time after the application of the study in the same center?
Which factors might affect these results? At the time of the study, we did not plan to answer the latter question, and the fact that it was not one of our objectives is one of the limitations of this study.
In our population, recurrent wheezing prevalence after 5 years remained stable. In large surveys, such as the ISAAC, Wheezing in infants -Chong Neto HJ et al.
mean interval between phase I and III was 7 years 1 ; in our center, the time interval between phases was shorter, and this may explain why our prevalence rate remained stable. However, there was a significant reduction in the severity of symptoms of recurrent wheezing, confirmed by a reduction in nocturnal symptoms, severe symptoms and emergency department visits, but there was no reduction in hospitalizations due to wheezing.
The drugs available for asthma treatment in the public health care system may have affected the severity of symptoms. Physician-diagnosed asthma has increased in the last 5 years, which, when associated with greater treatment availability, may have affected our results. The comparison of EISL phase I in Curitiba and São Paulo revealed that the use of antiasthma medications both for infants with fewer than three wheezing episodes and infants with recurrent wheezing was greater in Curitiba, and the severity of wheezing symptoms was greater in São Paulo. 14 We concluded that the prevalence of recurrent wheezing remained high and stable in Curitiba; these rates are lower than those found in some centers, but higher than those of many other cities participating in EISL. There was a significant reduction in wheezing severity among our population, but not in the rate of hospitalizations. These findings should be further investigated and compared with other cities participating in the survey.
The considerable increase in the number of children with physician-diagnosed asthma suggests that, in primary care, the term "asthma" has been used more often because the disease has been more identified, which may lead to better treatments and a reduction in the morbidity rates of this disease.
